Published in Cancer Res on December 15, 2007
Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One (2009) 3.89
Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells (2009) 2.68
Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng (2010) 2.66
Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells (2010) 2.54
The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc Natl Acad Sci U S A (2009) 2.07
Human bone marrow-derived MSCs can home to orthotopic breast cancer tumors and promote bone metastasis. Cancer Res (2010) 1.61
Trafficking mesenchymal stem cell engraftment and differentiation in tumor-bearing mice by bioluminescence imaging. Stem Cells (2009) 1.58
Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res (2009) 1.51
Magnetic resonance imaging of mesenchymal stem cells homing to pulmonary metastases using biocompatible magnetic nanoparticles. Cancer Res (2009) 1.42
Omental adipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors. Clin Cancer Res (2011) 1.38
Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization. Mol Med (2011) 1.31
Advances in mesenchymal stem cell-mediated gene therapy for cancer. Stem Cell Res Ther (2010) 1.29
Toward brain tumor gene therapy using multipotent mesenchymal stromal cell vectors. Mol Ther (2010) 1.18
Stem cells as vectors for antitumour therapy. Thorax (2010) 1.14
Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic. Prog Mol Biol Transl Sci (2010) 1.14
Targeting cancer stem cells: a new therapy to cure cancer patients. Am J Cancer Res (2012) 1.11
Nanoparticulate cellular patches for cell-mediated tumoritropic delivery. ACS Nano (2010) 1.09
Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Invest (2012) 1.09
To grab the stroma by the horns: from biology to cancer therapy with mesenchymal stem cells. Oncotarget (2013) 1.05
Differential mechanical response of mesenchymal stem cells and fibroblasts to tumor-secreted soluble factors. PLoS One (2012) 1.02
The role of mesenchymal stem cells in cancer development. Front Genet (2013) 1.02
Murine bone marrow-derived mesenchymal stem cells as vehicles for interleukin-12 gene delivery into Ewing sarcoma tumors. Cancer (2009) 1.01
Enhanced homing permeability and retention of bone marrow stromal cells by noninvasive pulsed focused ultrasound. Stem Cells (2012) 1.00
Platelet-derived growth factor BB mediates the tropism of human mesenchymal stem cells for malignant gliomas. Neurosurgery (2010) 0.98
Radiation increases invasion of gene-modified mesenchymal stem cells into tumors. Int J Radiat Oncol Biol Phys (2008) 0.98
Homing of Mesenchymal Stem Cells. Transfus Med Hemother (2008) 0.97
Mesenchymal Stem Cell-mediated delivery of the sodium iodide symporter supports radionuclide imaging and treatment of breast cancer. Stem Cells (2011) 0.97
Gene-modified mesenchymal stem cells protect against radiation-induced lung injury. Mol Ther (2012) 0.97
Stem cell-based therapies for cancer treatment: separating hope from hype. Nat Rev Cancer (2014) 0.96
Radiosensitivity of cancer-initiating cells and normal stem cells (or what the Heisenberg uncertainly principle has to do with biology). Semin Radiat Oncol (2009) 0.96
Image-guided, tumor stroma-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated NIS gene delivery. Mol Ther (2011) 0.93
Drug-loaded nanoparticle systems and adult stem cells: a potential marriage for the treatment of malignant glioma? Oncotarget (2013) 0.93
Regenerative stromal cell therapy in allogeneic hematopoietic stem cell transplantation: current impact and future directions. Biol Blood Marrow Transplant (2009) 0.92
Color-coded imaging of splenocyte-pancreatic cancer cell interactions in the tumor microenvironment. Cell Cycle (2008) 0.92
Concise review: Nanoparticles and cellular carriers-allies in cancer imaging and cellular gene therapy? Stem Cells (2010) 0.92
AMD3100-mediated production of interleukin-1 from mesenchymal stem cells is key to chemosensitivity of breast cancer cells. Am J Cancer Res (2011) 0.91
Application of bioluminescence imaging for in vivo monitoring of fungal infections. Int J Microbiol (2011) 0.91
Mesenchymal Stem/Stromal Cells in Stromal Evolution and Cancer Progression. Stem Cells Int (2015) 0.91
Regulation of the inflammatory profile of stromal cells in human breast cancer: prominent roles for TNF-α and the NF-κB pathway. Stem Cell Res Ther (2015) 0.90
The role of adipose-derived stem cells in breast cancer progression and metastasis. Stem Cells Int (2015) 0.90
Allogeneic tumor cell vaccines: the promise and limitations in clinical trials. Hum Vaccin Immunother (2013) 0.87
Homing and migration of mesenchymal stromal cells: How to improve the efficacy of cell therapy? World J Stem Cells (2016) 0.86
Intranasal delivery of mesenchymal stem cells significantly extends survival of irradiated mice with experimental brain tumors. Mol Ther (2013) 0.85
A specific subpopulation of mesenchymal stromal cell carriers overrides melanoma resistance to an oncolytic adenovirus. Stem Cells Dev (2012) 0.85
Establishment of animal model for the analysis of cancer cell metastasis during radiotherapy. Radiat Oncol (2012) 0.84
Integral role of platelet-derived growth factor in mediating transforming growth factor-β1-dependent mesenchymal stem cell stiffening. Stem Cells Dev (2013) 0.83
Targeting of mesenchymal stem cells to ovarian tumors via an artificial receptor. J Ovarian Res (2010) 0.83
Detection of circulating tumor cell subpopulations in patients with head and neck squamous cell carcinoma (HNSCC). PLoS One (2014) 0.83
Role of mesenchymal cells in the natural history of ovarian cancer: a review. J Transl Med (2014) 0.82
Radio-resistant mesenchymal stem cells: mechanisms of resistance and potential implications for the clinic. Oncotarget (2015) 0.82
Stromal targeting of sodium iodide symporter using mesenchymal stem cells allows enhanced imaging and therapy of hepatocellular carcinoma. Hum Gene Ther (2013) 0.82
Microenvironment, oncoantigens, and antitumor vaccination: lessons learned from BALB-neuT mice. Biomed Res Int (2014) 0.81
Among women who experience a recurrence after postmastectomy radiation therapy irradiation is not associated with more aggressive local recurrence or reduced survival. Breast Cancer Res Treat (2010) 0.81
Identification of galectin-1 as a critical factor in function of mouse mesenchymal stromal cell-mediated tumor promotion. PLoS One (2012) 0.81
Irradiation enhances susceptibility of tumor cells to the antitumor effects of TNF-α activated adipose derived mesenchymal stem cells in breast cancer model. Sci Rep (2016) 0.80
A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer. Biomaterials (2016) 0.79
Close interactions between mesenchymal stem cells and neuroblastoma cell lines lead to tumor growth inhibition. PLoS One (2012) 0.79
Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models. Oncotarget (2016) 0.78
Circulating Tumor Cell Composition in Renal Cell Carcinoma. PLoS One (2016) 0.78
Specific chemotaxis of magnetically labeled mesenchymal stem cells: implications for MRI of glioma. Mol Imaging Biol (2012) 0.78
Mesenchymal Stromal Cell Dependent Regression of Pulmonary Metastasis from Ewing's. Front Pediatr (2014) 0.78
The role of tumor microenvironment in therapeutic resistance. Oncotarget (2016) 0.78
Effects of diagnostic ultrasound-targeted microbubble destruction on the homing ability of bone marrow stromal cells to the kidney parenchyma. Eur Radiol (2015) 0.77
Gene-directed enzyme prodrug therapy. AAPS J (2014) 0.77
The role of chemoattractant receptors in shaping the tumor microenvironment. Biomed Res Int (2014) 0.77
Dihydropyrimidine Dehydrogenase Is a Prognostic Marker for Mesenchymal Stem Cell-Mediated Cytosine Deaminase Gene and 5-Fluorocytosine Prodrug Therapy for the Treatment of Recurrent Gliomas. Theranostics (2016) 0.77
Mesenchymal stem cells develop tumor tropism but do not accelerate breast cancer tumorigenesis in a somatic mouse breast cancer model. PLoS One (2013) 0.77
Adult mesenchymal stem cells and the NO pathways. Proc Natl Acad Sci U S A (2013) 0.77
Mesenchymal stem cells as a novel vaccine platform. Front Cell Infect Microbiol (2012) 0.76
Use of genetically engineered stem cells for glioma therapy. Oncol Lett (2015) 0.75
Patient-derived mesenchymal stem cells as delivery vehicles for oncolytic virotherapy: novel state-of-the-art technology. Oncolytic Virother (2015) 0.75
Sphingosine 1-Phosphate Receptor 2 Regulates the Migration, Proliferation, and Differentiation of Mesenchymal Stem Cells. Int J Stem Cell Res Ther (2015) 0.75
Dynamic Tracking Human Mesenchymal Stem Cells Tropism following Smoke Inhalation Injury in NOD/SCID Mice. Stem Cells Int (2016) 0.75
Characterization of the Tumor Microenvironment and Tumor-Stroma Interaction by Non-invasive Preclinical Imaging. Front Oncol (2017) 0.75
Prognostic significance of TRAIL-R3 and CCR-2 expression in tumor epithelial cells of patients with early breast cancer. BMC Cancer (2017) 0.75
Human mesenchymal stem cells preferentially migrate toward highly oncogenic human hepatocellular carcinoma cells with activated EpCAM signaling. Oncotarget (2017) 0.75
Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med (1986) 17.64
Marrow stromal cells as stem cells for nonhematopoietic tissues. Science (1997) 17.06
Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest (1997) 7.58
Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst (2004) 5.39
Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res (2005) 5.17
Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res (2002) 4.99
Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res (1999) 4.17
The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells (2007) 3.68
Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol (2004) 3.41
Role of CCR8 and other chemokine pathways in the migration of monocyte-derived dendritic cells to lymph nodes. J Exp Med (2004) 2.68
CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett (2007) 2.43
MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines. Blood (2006) 2.24
Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. J Cell Biochem (2007) 1.86
Recent advances into the understanding of mesenchymal stem cell trafficking. Br J Haematol (2007) 1.84
Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des (2002) 1.59
Basic fibroblast growth factor controls migration in human mesenchymal stem cells. Stem Cells (2006) 1.52
Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. J Neurooncol (2007) 1.42
Mobilization of bone marrow stem cells by granulocyte colony-stimulating factor ameliorates radiation-induced damage to salivary glands. Clin Cancer Res (2006) 1.38
Human mesenchymal stem cells: progenitor cells for cartilage, bone, fat and stroma. Curr Top Microbiol Immunol (2000) 1.37
Vascular endothelial growth factor A contributes to glioma-induced migration of human marrow stromal cells (hMSC). Exp Neurol (2006) 1.32
Migration of mesenchymal stem cells to heart allografts during chronic rejection. Transplantation (2003) 1.26
Adult bone-marrow-derived mesenchymal stem cells contribute to wound healing of skin appendages. Cell Tissue Res (2006) 1.21
CCR2: from cloning to the creation of knockout mice. Chem Immunol (1999) 1.01
Increased longevity of hematopoiesis in continuous bone marrow cultures and adipocytogenesis in marrow stromal cells derived from Smad3(-/-) mice. Exp Hematol (2005) 0.99
Comparison of the efficiency of transduction of leukemic cells by fiber-modified adenoviruses. Hum Gene Ther (2004) 0.99
The role of PDGF in radiation oncology. Radiat Oncol (2007) 0.97
From agonist to antagonist: Fab fragments of an agonist-like monoclonal anti-beta(2)-adrenoceptor antibody behave as antagonists. Mol Pharmacol (2000) 0.96
Immunomodulatory properties of FK734, a humanized anti-CD28 monoclonal antibody with agonistic and antagonistic activities. Transplantation (2007) 0.92
Vaccination with leukemia cells expressing cell-surface-associated GM-CSF blocks leukemia induction in immunocompetent mice. Oncogene (2006) 0.87
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell (2006) 8.59
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol (2005) 7.83
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther (2006) 7.73
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet (2009) 5.82
Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst (2011) 5.79
Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst (2004) 5.39
MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood (2008) 5.23
Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res (2005) 5.17
Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res (2002) 4.99
Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One (2009) 3.89
MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci U S A (2006) 3.80
Should randomized clinical trials be required for proton radiotherapy? J Clin Oncol (2008) 3.72
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood (2008) 3.67
MicroRNA 29b functions in acute myeloid leukemia. Blood (2009) 3.19
Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys (2005) 3.19
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood (2003) 3.18
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood (2006) 3.13
Estimation of α/β for late rectal toxicity based on RTOG 94-06. Int J Radiat Oncol Biol Phys (2011) 2.96
Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2006) 2.90
Functional proteomic profiling of AML predicts response and survival. Blood (2008) 2.90
MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood (2005) 2.88
Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys (2006) 2.82
Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest (2009) 2.80
4D Proton treatment planning strategy for mobile lung tumors. Int J Radiat Oncol Biol Phys (2007) 2.80
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst (2008) 2.77
Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer (2012) 2.76
Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J Clin Oncol (2009) 2.75
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov (2013) 2.74
Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells (2011) 2.74
Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells (2009) 2.68
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol (2010) 2.58
EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. Cancer Cell (2011) 2.54
Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells (2010) 2.54
Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood (2006) 2.45
Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin (2010) 2.45
Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia. Nat Med (2007) 2.38
Assessing respiration-induced tumor motion and internal target volume using four-dimensional computed tomography for radiotherapy of lung cancer. Int J Radiat Oncol Biol Phys (2007) 2.35
[18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol (2005) 2.30
Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys (2007) 2.28
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res (2006) 2.23
A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell (2006) 2.20
Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res (2008) 2.17
Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res (2005) 2.09
Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys (2009) 2.08
The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc Natl Acad Sci U S A (2009) 2.07
Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood (2002) 2.03
Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther (2002) 2.03
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol (2010) 2.02
Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression. J Biol Chem (2006) 2.01
Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys (2009) 2.01
Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer (2010) 2.00
Wnt/beta-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line. J Cell Sci (2007) 1.98
Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. Cancer Res (2009) 1.96
Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2004) 1.94
A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin Cancer Res (2006) 1.92
Image-guided radiation therapy for non-small cell lung cancer. J Thorac Oncol (2008) 1.90
Implementation and validation of a three-dimensional deformable registration algorithm for targeted prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys (2005) 1.87
Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys (2002) 1.85
Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther (2006) 1.84
The risk of developing a second cancer after receiving craniospinal proton irradiation. Phys Med Biol (2009) 1.83
Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles. Int J Hematol (2007) 1.83
Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS One (2012) 1.82
Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia. Leuk Lymphoma (2012) 1.80
Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Cancer Res (2008) 1.78
A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res (2008) 1.77
Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein. Cancer (2004) 1.75
Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther (2006) 1.74
Assessment of gross tumor volume regression and motion changes during radiotherapy for non-small-cell lung cancer as measured by four-dimensional computed tomography. Int J Radiat Oncol Biol Phys (2007) 1.74
Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2004) 1.73
Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys (2010) 1.72
TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res (2011) 1.71
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood (2013) 1.70
Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res (2007) 1.67
Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer. Int J Radiat Oncol Biol Phys (2010) 1.67
Cerebrovascular disease risk in older head and neck cancer patients after radiotherapy. J Clin Oncol (2008) 1.66
Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys (2012) 1.65
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica (2010) 1.65
Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys (2005) 1.63
Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer (2011) 1.63
Clonogenic cell survival assay. Methods Mol Med (2005) 1.61
Are the results of RTOG 0617 mysterious? Int J Radiat Oncol Biol Phys (2012) 1.60
The novel triterpenoid C-28 methyl ester of 2-cyano-3, 12-dioxoolen-1, 9-dien-28-oic acid inhibits metastatic murine breast tumor growth through inactivation of STAT3 signaling. Cancer Res (2007) 1.60
MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res (2011) 1.59
Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer. Am J Surg Pathol (2009) 1.59
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood (2003) 1.57
Effects of interfractional motion and anatomic changes on proton therapy dose distribution in lung cancer. Int J Radiat Oncol Biol Phys (2008) 1.56
Status of particle therapy for lung cancer. Acta Oncol (2011) 1.56